Special Investigation for Booster Dose of Comirnaty in Children Ages 6 Months Though 4 Years

Immunogenicity, Safety and Tolerability, of Chiron Meningococcal C Conjugate Vaccine Administered to Healthy Premature and Non Premature Children of 3 Months of Age

NCT00310674 ·Status: COMPLETED ·Phase: PHASE3

Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 Years

NCT01423084 ·Status: COMPLETED ·Phase: PHASE3

Effectiveness of Inactivated COVID-19 Vaccine of the First Booster Dose

NCT05367895 ·Status: UNKNOWN

COVAXIN in a Pediatric Cohort

NCT04918797 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life

NCT01214837 ·Status: COMPLETED ·Phase: PHASE3

Safety, Tolerability and Immunogenicity of a Third Dose of One of Four Different Formulations of rMenB + MenACWY Combination Vaccine in Adolescents Who Previously Received the Same Study Vaccines

NCT01367158 ·Status: COMPLETED ·Phase: PHASE2

Immunogenicity and Safety of Meningococcal Vaccine GSK134612 Given as 1 or 2 Doses to Healthy 9-12 Months Old Toddlers.

NCT00471081 ·Status: COMPLETED ·Phase: PHASE2

Safety and Immunogenicity of Novartis Meningococcal B Vaccine When Administered to Immunocompromised Children and Adolescents Compared to Healthy Subjects.

NCT02141516 ·Status: COMPLETED ·Phase: PHASE3

Safety and Immunogenicity of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Children Aged 12-59 Months.

NCT00310817 ·Status: COMPLETED ·Phase: PHASE2

Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1

NCT01717638 ·Status: COMPLETED ·Phase: PHASE3

Extension Study of V72P13 to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster or as a Two-dose Catch-up to Healthy Toddlers

NCT00847145 ·Status: COMPLETED ·Phase: PHASE3

Determining Reactogenicity and Immunogenicity of Delayed COVID-19 Vaccine Schedule in Children

NCT05329064 ·Status: UNKNOWN ·Phase: PHASE4

Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine Administered to Healthy Adolescents According to Different Vaccination Schedules

NCT00661713 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Safety and Efficacy of BK1310 Intramuscular Injection in Healthy Infants

NCT03188692 ·Status: COMPLETED ·Phase: PHASE3

Lot-to-lot Consistency of an Inactivated SARS-CoV-2 Vaccine Between Different Workshops in Healthy Children Aged 3-17 Years

NCT05112913 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4

Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of Booster Doses of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received One or Four Doses of the Same Vaccine

NCT01027351 ·Status: COMPLETED ·Phase: PHASE2

A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children

NCT04816643 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

A Real-world Evidence Study of BNT162b2 mRNA Covid-19 Vaccine Among Children in Brazil

NCT05403307 ·Status: COMPLETED

Study of a Single Dose of Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine (SP284) in Japanese Subjects

NCT01519713 ·Status: COMPLETED ·Phase: PHASE3

Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 Years

NCT05468736 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Safety, Tolerability and Immunogenicity of Three Doses of Novartis Meningococcal B Vaccine When Administered to Healthy At-risk Adults

NCT00560313 ·Status: COMPLETED ·Phase: PHASE2

Safety, Tolerability and Immunogenicity of Two Different Formulations of Meningococcal B Recombinant Vaccine, When Administered to Healthy Infants

NCT00433914 ·Status: COMPLETED ·Phase: PHASE2

A Study of the Immunogenicity and Safety of SCTV01C in Population Aged ≥12 Years and Previously Vaccinated With Inactivated COVID-19 Vaccine

NCT05239975 ·Status: WITHDRAWN ·Phase: PHASE2

Safety & Immunogenicity of 1 Dose of GSK134612 in Children 12-14 Months and 3-5 Years Old

NCT00196976 ·Status: COMPLETED ·Phase: PHASE2

Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of a Booster Dose of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received Three Doses of the Same Vaccine

NCT01026974 ·Status: COMPLETED ·Phase: PHASE2